Spindler et al. were among the first to analyze the concordance of KRAS mutation between tissue and cfDNA, obtaining a sensitivity of 78% and absolute specificity, as none of the patients without mutations in primary tumor tissue showed positive plasma samples [95]. The gene discussed is KRAS; the disease is neoplasm.